OM
NPCE icon

Opaleye Management’s Neuropace NPCE Stock Holding History

Opaleye Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-116,324
Closed -$436K – 46
2022
Q3 		$436K Buy
116,324
+26,224
+29% +$126K 0.18% 36
2022
Q2 		$446K Buy
+90,100
New +$595K 0.2% 40

Other funds holding NPCE

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Opaleye Management's NPCE Position: Q4 2022 in Review

Opaleye Management sold out of Neuropace (NPCE) in Q4 2022, closing a stake of 116,324 shares — an estimated $436K sold.

Opaleye Management first reported a position in NPCE in Q2 2022 and held it in 2 quarters. The position peaked at $446K in Q2 2022. 24 funds tracked by Wall St. Rank hold NPCE as of Q4 2022.

  • Opaleye Management reported no remaining Neuropace position as of Q4 2022 after selling out during the quarter.
  • Opaleye Management sold 116,324 Neuropace shares in Q4 2022, an estimated $436K.
  • Opaleye Management first reported a position in Neuropace in Q2 2022 and held it in 2 quarters.
  • Opaleye Management's Neuropace position peaked at $446K in Q2 2022.
  • 24 funds tracked by Wall St. Rank held Neuropace as of Q4 2022.

Based on Opaleye Management's 13F filing for Q4 2022, filed 10 Feb 2023.